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Abstract: Stroke is a leading cause of death and disability and is responsible for a significant economic
burden. Sarcopenia and cognitive dysfunction are common consequences of stroke, but there is less
awareness of the concurrency of these conditions. In addition, few reviews are available to guide
clinicians and researchers on how to approach sarcopenia and cognitive dysfunction as comorbidities
after stroke, including how to assess and manage them and implement interventions to improve
health outcomes. This review synthesises current knowledge about the relationship between post-
stroke sarcopenia and cognitive dysfunction, including the physiological pathways, assessment tools,
and interventions involved.
Keywords: stroke; post stroke; sarcopenia; cognitive dysfunction
1. Introduction
Stroke is an episode of acute neurological dysfunction caused by the interruption
of blood supply to the brain, leading to the death of brain cells. Medical interventions
for stroke that have been successful in animal models have had poor efficacy in clinical
studies. The complexity and heterogeneity of human diseases and related comorbidities
may partly explain this, which may render neuroprotective drugs ineffective in clinical
practice [1]. Stroke is linked to vascular dementia, which can be caused by chronic re-
duced blood flow to the brain [2] or may result from acute strategically located lesions,
such as in the thalamus or inferior parietal lobule. The possible underlying biological
mechanisms linking stroke and vascular dementia include oxidative stress, inflammation,
and alterations to microribonucleic acid and brain proteins [2–5]. In addition, ageing and
comorbidities have been recognised as major risk factors related to this link [1,5]. However,
not all people who suffer a stroke are likely to develop vascular dementia. Understanding
the developing trajectory between the two conditions and identifying biological mecha-
nisms that link stroke events and the development of vascular dementia would enable
the recommendation of lifestyle changes and/or novel interventions for cognitive reserve
and flexibility. Post-stroke cognitive dysfunction—that is, diminished or impaired mental
and/or intellectual function after stroke [6]—could be ameliorated by early intervention.
Another adverse health outcome of stroke is post-stroke sarcopenia, defined as the loss
of muscle mass and function after a stroke [7]. Cognitive dysfunction and sarcopenia appear
to be reported simultaneously in patients with stroke [8], indicating the likely parallel
progression of comorbid sarcopenia and cognitive decline; however, the links between post-
stroke sarcopenia and post-stroke cognitive dysfunction and its underlying mechanisms
have rarely been investigated simultaneously. In Australia, the Geelong Osteoporosis
Study reported that markers of sarcopenia (slow gait speed, poor handgrip strength,
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and low muscle density) were negatively associated with performance in some domains of
cognitive function, including psychomotor function, visual learning, attention, and overall
cognitive function in a general geriatric population [9,10]. These findings align with those
of other studies on the links between sarcopenia and cognitive dysfunction in ageing [11,12].
Given the emerging evidence that links sarcopenia with cognitive dysfunction, it is possible
that they share common mechanisms or underlying physiology [13]. If there are clear links
between sarcopenia and cognitive dysfunction after stroke, the co-design of interventions
for post-stroke sarcopenia and cognitive dysfunction may be achievable and cost-effective
and produce greater clinical gain [14].
This review presents a critical appraisal of the scientific literature on the association
between post-stroke sarcopenia and cognitive dysfunction and their underlying mech-
anisms. It describes the current assessment tools, summarises up-to-date interventions,
identifies future directions, and finally proposes novel screening tools for use in population-
based studies.
2. Post-Stroke Cognitive Dysfunction
Cognitive dysfunction is more common in people with stroke compared to healthy
age-matched adults. For example, an Irish cross-sectional study [15] examined the odds
of nursing home residents who had experienced a stroke having cognitive dysfunction
compared to residents without stroke at the time of admission. Among 643 residents,
the prevalence of cognitive dysfunction and dementia was significantly higher in those
who had experienced a stroke before admission. Further, post-stroke cognitive dysfunc-
tion was a predictor of negative physical and mental health outcomes, such as mortality,
dependency, mood disorders, and hospitalisations [16], and an independent indicator of
stroke recurrence [17]. Fitri et al. [18] found that of 38 patients (39.5% women) after stroke,
17 (44.7%) were cognitively impaired. Cognitive function was assessed using the Mini
Mental State Examination (MMSE), forward digit span and backward digit span tests.
A Norwegian longitudinal study of 617 patients with stroke (mean age 72 ± 12,
42% women) investigated the effect of stroke severity on cognitive dysfunction [19]. The as-
sessed domains of cognitive function included attention, executive function, memory,
language, and perceptual-motor function. Cognitive function was assessed at three months
and/or 18 months after stroke. The severity of cognitive dysfunction and stroke were
determined by the Diagnostic and Statistical Manual of Mental Disorders DSM-5 criteria
and the National Institutes of Health Stroke Scale (NIHSS), respectively. This study found
that executive function and language improved over the stroke recovery period; post-stroke
cognitive dysfunction was common for all stroke subtypes at the two follow-up points.
Even a minor stroke appeared to be a risk factor for developing cognitive dysfunction.
A longitudinal study in Norway [20] included 324 patients with minor stroke followed
at 3-month and 12-month intervals (37 patients were lost to follow-up). The authors ob-
served cognitive improvement during the follow-up period, but the prevalence of cognitive
dysfunction remained high (29.5%) 12 months after stroke.
Prevalence estimates of post-stroke cognitive dysfunction vary between studies,
depending on the definitions, subtypes, and severity of the stroke; the length of follow-up
periods; and the cognition assessment tools used [21,22]. A systematic review reported that
the prevalence of cognitive dysfunction was 14–88% among 11 studies for post-intracerebral
haemorrhage, which is typically associated with a higher prevalence of dementia than
ischaemic stroke [23]. Together, these studies emphasise the magnitude and significance of
cognitive impairment following stroke. The studies included in this section are summarised
in Table 1.
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3. Post-Stroke Sarcopenia or Cachexia
Cachexia is a condition associated with general ill-health, malnutrition, extreme
weight loss, and muscle wasting and is a symptom of many chronic conditions [24].
Meanwhile, sarcopenia is often described as age-related muscle mass and functional
decline [25]. In the stroke literature, the terms sarcopenia and cachexia appear to be
employed interchangeably, possibly because researchers from different disciplines have
a different understanding of these conditions. In general, sarcopenia is more accurately
defined as age-based skeletal muscle decline, while cachexia is diseases-based [24]. Recently,
there have been suggestions that low muscle strength, rather than low muscle mass,
be considered the major determinant of sarcopenia [25]. Thus, to further investigate
whether the loss of muscle mass and function is disease-based or age-related, we suggest
that sarcopenia and cachexia are not regarded as interchangeable.
Scherbakov et al. [26] investigated changes in body composition and body weight
after ischemic stroke and their association with functional outcomes. They studied 67 con-
secutive patients (42% women, mean age 69 years, mean body mass index 27.0) with
acute ischemic stroke and mild to moderate neurological deficit assessed using the NIHSS.
Assessment data were obtained during the acute phase (4 ± 2 days) and at the 12-month
follow-up. Body composition was examined by dual-energy X-ray absorptiometry (DXA).
Body weight loss ≥5% within one year and additional clinical signs were considered to
denote cachexia. In this cohort study, one in five patients with ischemic stroke developed
cachexia within 12 months of s stroke. Cachexia was associated with the lowest functional
and physical capacity.
There is no universally accepted operational definition of sarcopenia [27,28], mean-
ing that the prevalence estimates of post-stroke sarcopenia vary. A study in the United
States of America (USA) [29] aimed to determine the prevalence of sarcopenia in post-
stroke survivors using multiple methods and reported a prevalence of 14–18%. Su et al.’s
systematic review and meta-analysis [30] reported that the pooled prevalence estimate
of post-stroke sarcopenia was 42% (95% CI: 33–52%, I2 = 91%) in patients with stroke.
This review included seven studies, six from Asian countries and one from the USA. The
authors concluded that longitudinal studies are needed to establish the incidence estimates
of sarcopenia after stroke.
Skeletal muscle mass alone seems to be an indicator of health outcomes after stroke.
Ohyama et al. [31] examined the association between lean mass and clinical outcomes of
acute ischemic stroke (severe neurological impairment and functional status on admission).
Of 164 Japanese patients (34% women), 101 (62%) were identified as having lean mass
deficits, determined by bioelectrical impedance analysis (BIA). This study found that
lean mass deficits were not only associated with a worse status of conditions (i.e., severe
neurological impairment and functional status) at admission but with poor functional
outcomes and longer durations of hospital stay.
Consistent with the above, Nagano et al. [32] suggested that preserving muscle mass is
associated with better functional recovery in post-stroke patients with sarcopenia. This ret-
rospective study included 272 patients (44% with sarcopenia) recruited from hospitals in
Japan. Sarcopenia was assessed as the loss of lean mass plus decreased handgrip strength,
according to the Asian Working Group for Sarcopenia’s (AWGS) definition [33]. The Func-
tional Independence Measure (FIM) was used to assess stroke recovery. The authors
suggested that exercise and nutritional interventions were needed to reduce sarcopenia
and achieve better stroke recovery. Matsushita et al. [34] examined the relationship be-
tween sarcopenia (using the European Working Group on Sarcopenia in Older People’s
definition [35]) and ability to perform daily living activities (assessed using the FIM motor
domain score [36]) in post-stroke patients after rehabilitation intervention. This study
involved 267 participants (56% men), 129 with sarcopenia. The results suggested that
sarcopenia independently predicts the inability to engage in daily living activities after
rehabilitation for men; a potential sex interaction in this relationship means that further
investigation is needed.
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Concurrent sarcopenia and excessive fat accumulation is known as sarcopenic obesity
and is more common with increasing age and adiposity [37]. Matsushita et al. revealed that
sarcopenic obesity was independently associated with lower ability to perform activities of
daily living in post stroke-patients undergoing a convalescent rehabilitation program [38].
In this study, sarcopenia was defined using handgrip strength and the AWGS’s muscle
mass index, while obesity was defined as body fat mass index. Of 376 patients (mean age
78 years), 17% were obese, 32% had sarcopenia, and 28% had sarcopenic obesity. Sarcope-
nia obesity was independently associated with lower activities of daily living capability;
however, obesity or sarcopenia alone were not. The studies included in this section are
summarised in Table 1.
4. Are Post-Stroke Sarcopenia and Cognitive Dysfunction Comorbid?
Evidence emerging from observational and experimental studies has shown that
human body composition and brain function are linked [9,10,13,39–43]. Although sarcope-
nia and cognitive dysfunction are often considered separate multidimensional concepts,
they may have common risk factors and biological pathways. In general, advanced age
contributes to the decline of skeletal muscle health and cognitive function [9,10]. In older pa-
tients in hospital settings, sarcopenia and cognitive dysfunction are strongly associated [44].
Complex genetic and modifiable factors, such as decreased blood supply, reduced social en-
gagement, lack of exercise, malnutrition, and reduced neurological performance interplay
in this relationship during ageing [45]. Recently, the concept of muscle–cognition crosstalk
has received substantial attention in the literature [46]; however, stroke-related sarcopenia
and cognitive dysfunction are rarely discussed as comorbidities. We acknowledge the com-
plexity of discussing the muscle–cognition relationship in a disease context; disease may
exacerbate the natural effects of ageing and accelerate the co-development of sarcopenia
and cognitive dysfunction.
The current literature contains little epidemiological evidence about the overlap of
post-stroke sarcopenia and cognitive dysfunction. The lack of consensus about definitions,
assessment tools and techniques in stroke-related cognitive dysfunction and sarcopenia
further reduce the quality of the evidence. Given the high prevalence of the two conditions
in population-based studies and in hospitalised older patients [44], studies are needed to
determine whether sarcopenia and cognitive dysfunction can be considered comorbidities
and associated by definition in stroke populations.
5. What Are the Potential Underlying Biological Mechanisms If Post-Stroke Sarcopenia
and Cognitive Dysfunction Are Comorbid?
Sui et al have identified a potential role of inflammation linking muscle density
and visual learning and memory in a population-based study [10]; in stroke literature,
the role of inflammation markers is less clear and inconsistent. A recent review highlighted
that changes in molecular biomarkers such as C-reactive protein (CRP), interleukin 6
(IL-6) and IL-10 in blood, urine, and other body fluids are associated with post-stroke
cognitive decline [47]. Yoshimura et al.’s [48] retrospective cohort study investigated the
association between systemic inflammation, post-stroke sarcopenia, and the functional
consequences (motor, cognitive function, and overall) in post-stroke patients. The study
included 204 Japanese patients (47% women, mean age 74.1 years) who were admitted
to rehabilitation wards between 2015 and 2017. A modified Glasgow Prognostic Score,
determined by the serum levels of CRP and albumin, was adopted to evaluate systemic
inflammation (participants who had acute or chronic high-grade inflammatory diseases
were excluded). Sarcopenia was identified using the AWGS definition, and the outcome
was assessed using the FIM. The authors identified 39.7% patients as having sarcopenia and
reported that inflammation was independently associated with sarcopenia and negative
motor outcomes. However, sarcopenia was not associated with cognitive dysfunction after
adjusting for confounders. For future research, Yoshimura et al. recommended models
that include multiple paths of influence and interactions, suggesting that inflammation
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cannot be excluded as a potential mechanism linking sarcopenia and cognitive impairment
after stroke.
Brain-derived neurotrophic factor (BDNF), a neurotrophin growth factor that is impor-
tant for nervous system development and the survival of existing neurons, is considered
a protective factor for stroke. An integrative review has reported lower BDNF levels in
patients with stroke [49]; in one data-driven study, stroke patients with low levels of serum
BDNF had significantly higher prevalence of cognitive dysfunction than healthy controls.
Another study found that BDNF levels increased during motor rehabilitation following
ischemic stroke [50]. A randomised controlled trial (RCT) in Taiwan compared the effect
of high-intensity interval training (HIIT) and moderate-intensity continuous training on
serum BDNF and other outcomes in stroke patients. This study found that HIIT was more
effective, because increased BDNF promoted neuronal activity and induced better health
outcomes. Future studies that focus on neurologic recovery using intensity-dependent
exercise should consider BDNF as a marker [51].
6. What Assessment Tools Are Available for Post-Stroke Sarcopenia?
The standard techniques for assessing body composition—DXA and peripheral quan-
titative computed tomography (pQCT) (detailed in the following section)—may also be
applied in the stroke population. However, in some circumstances they may not be suit-
able as many assessment tool for muscle mass and volumes are sensitive to movement
(e.g., pQCT and DXA), and people suffering from stroke may not be able to perform physi-
cal performance (e.g., walking and HGS testing). For example, Jung et al. [52] argued that
an alternative assessment tool for post-stroke sarcopenia is needed, because the current
suggested measurement tool (e.g., DXA) is age-related and limited to stroke-specific sar-
copenia, especially for muscle performance and strength. Their study included 40 patients
(56% women; mean age 67 years, SD = 15.4) who had experienced stroke but could walk
independently. Muscle mass was assessed by measuring ultrasonographic muscle thick-
ness [48] and by measuring skeletal lean mass using bioelectrical impedance analysis (BIA).
Muscle strength was assessed by the Medical Research Council Sum-Score (obtained by
calculating the muscle strength scores using manual muscle testing for the upper and lower
limbs) [52], and muscle strength was also assessed by evaluate handgrip strength (obtained
from a digital dynamometer). Physical performance was measured by the Berg Balance
Scale [53] and by a 4-meter gait speed test. The correlations between each assessment for
muscle mass, muscle strength, and muscle performance were examined and stroke severity,
comorbidity, and nutritional status were considered as confounders. The results supported
Jung et al.’s assertion that their proposed alternative measurements could be used to assess
sarcopenia in stroke patients.
7. What Assessment Tools Are Available for Cognitive Dysfunction?
Montreal Cognitive Assessment (MoCA) is commonly used in the assessment of
post-stroke cognitive function in patients [54]. In population studies, general cognitive dys-
function is commonly assessed using the MMSE or its modified versions. The MMSE is a
valid and reliable tool and is used worldwide [55]. Recently, computer-based neuropsycho-
logical tests have been developed to evaluate cognitive function in the domains of memory,
executive function, psychomotor function, information processing, and language [56].
The DSM-5 provides criteria for the diagnosis of neurocognitive disorders, including
dementia and Alzheimer’s disease. Structured clinical interviews are used in combination
with neuropsychology tests to identify individuals who may develop or already have
dementia or Alzheimer’s disease for diagnostic and research purposes. Neuropsychologi-
cal tests, together with neuroimaging techniques, have been used to identify early-stage
Alzheimer’s disease in people with mild cognitive dysfunction [57]. Epidemiological stud-
ies are needed to obtain normative data in each cognitive domain for diagnostic purposes.
Biomedicines 2021, 9, 223 6 of 14
8. What Interventions Exist for Post-Stroke Rehabilitation, and What Are the Future
Directions in the Context of Brain-Muscle Crosstalk?
Current post-stroke rehabilitation interventions treat muscle function (mainly motor
function) and cognitive function separately. Irisawa et al.’s prospective study included
179 patients recruited from two stroke rehabilitation units in Japan [58]. Lean mass was
assessed by BIA and nutrition status using the Geriatric Nutritional Risk Index. The ca-
pability of daily living (FIM scores) was measured at admission and four weeks later.
The results showed that high skeletal muscle mass relative to body weight and better nutri-
tional status was significantly associated with FIM scores at four weeks; no sex differences
were identified. The authors suggested that muscle mass maintenance through nutritional
management is essential for functional recovery in stroke patients. However, this study
did not assess body composition changes during recovery or the evaluate muscle strength,
so this omission provides some suggestion that the possible morbid characteristics of
sarcopenia and cognitive dysfunction are not considered in the clinical settings.
Lathuiliere et al. [14] reviewed the evidence for nutritional and pharmacological
interventions to prevent muscle wasting in stroke survivors. This review analysed eight
RCTs and two cohort studies and could not identify an effective nutritional intervention;
however, they noted that amino acid supplementation and anabolic steroid administration
(separately) appeared to prevent a loss of muscle mass in post-stroke sarcopenia. Cognitive
outcomes were not assessed in this study.
In a double-blinded RCT, Yoshimura et al. [59] examined whether a leucine-enriched
amino acid supplement could improve sarcopenia conditions (muscle weakness and loss of
muscle mass) in post-stroke patients over eight weeks. The study involved 44 post-stroke
older patients (21 in the intervention group and 23 in the control group) with sarcopenia
(defined using AWGS criteria). Both groups undertook resistance training and a post-stroke
rehabilitation program. Outcomes measures, including physical function, appendicular
muscle mass, and muscle strength, were measured at baseline and after the intervention.
The leucine-enriched amino acid supplementation was shown to reduce sarcopenia.
Ihle-Hansen et al.’s [60] 18-month RCT examined the effects of individualized regu-
lar coaching and exercise on post-stroke cognition. The Trail Making Test A and B and
MMSE were used to assess cognition, with data collected three and 21 months after stroke.
Of 362 patients aged 72 years (39.5% women), 177 patients were in the intervention group
and 185 were in the control group (usual care). This study did not detect a clinically signifi-
cant difference in cognition between the two groups; however, increased adherence to the
intervention was associated with improved cognition, suggesting an interaction between
cognitive function improvement and motivation. The authors suggested incorporating
cognitive interventions into cardiac rehabilitation.
Dysphagia (difficulty in swallowing) is considered to be associated with stroke-
induced sarcopenia; however, a retrospective cohort study in Japan [61] revealed a positive
effect of whole-body exercise on clinical outcomes including dysphagia in stroke patients
undergoing rehabilitation. This study included 637 patients (51% women, 23% with dys-
phagia) with a mean age of 73 years. Dysphagia was assessed using the Food Intake Level
Scale. The intervention included a chair stand exercise (median daily frequency = 36) in
addition to the convalescent rehabilitation program. The results showed that chair-stand
exercise was independently associated with reduced dysphagia.
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9. Is Population Screening for Sarcopenia and Cognitive Dysfunction Needed to
Prevent Stroke?
9.1. Pre-Stroke Sarcopenia
In previous sections, we demonstrated that body composition alterations, including
sarcopenia, are a consequence of stroke. Interestingly, sarcopenia may also be a risk
factor for the onset of stroke. Minn and Suk [62] conducted a community-based cross-
sectional study involving 722 participants (age range 50–75 years) without stroke and
dementia; based on brain and muscle scans, they concluded that increased lean mass may
protect against brain structure changes and against ischemic stroke, particularly in men.
Nozoe et al. [63] investigated the association between sarcopenia and the severity of stroke.
Pre-stroke sarcopenia was assessed using a questionnaire (SARC-F) and stroke severity
using the NIHSS. In 183 patients (44% women, 15% with pre-stroke sarcopenia), pre-stroke
sarcopenia was a predictor of severe stroke before and after adjusting for confounders.
A prospective cohort study [64] by the same research group investigated the association
between pre-stroke sarcopenia (determined by SARC-F) and functional outcomes after
stroke (using a modified Rankin Scale score) at three months in patients with acute stroke.
This study involved 152 patients (47% women, 18 with pre-stroke sarcopenia) with a mean
age of 76 years. Patients with pre-stroke sarcopenia were seven times more likely to develop
poor health outcomes at the assessment endpoint.
A South Korean retrospective cohort study [65] examined the association between
existing sarcopenia (assessed within two weeks of hospitalisation) at the onset of stroke
and functional recovery six months after stroke. This study included 194 hemiplegic post-
stroke patients. The results revealed that patients with pre-existing sarcopenia were almost
three times more likely to have poor clinical health outcomes at six months. Additionally,
they reported a sex-specific difference, in that women were more than twice as likely to
develop poor outcomes as men.
Note that the mechanisms linking pre-stroke sarcopenia and clinical stroke outcomes
are unclear. One reason for this could be reduced blood flow. The presence of sarcopenia,
lack of physical activity, and poor nutrition are independent risk factors for both stroke
and sarcopenia. This could reflect the fact it is more difficult to rehabilitate someone with
sarcopenia because of pre-existing muscle weakness, rather than sarcopenia being a specific
risk factor for more severe stroke.
Population-based studies help identify risk factors and mechanisms before the onset of
certain diseases. Modifiable risk factors of stroke, such as hypertension, diabetes mellitus,
obesity, tobacco smoking, hyperlipidaemia, poor diet/nutrition, and physical inactivity [66],
are considered in large-scale cohort studies. Both sarcopenia and cognitive dysfunction
among older adults can be screened at the population level. Therefore, coexisting sarcopenia
and cognitive dysfunction are assessable in a population-based study, enabling stroke to
be predicted and the underlying pathological pathways to be understood. The studies
included in this session are summarised in Table 1.
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Table 1. Summary of key studies included in the literature review.
Author, Year; Country/Region Study Type/Follow-Up Period Aim Participant Characteristics Results (Key Findings)
Post-stroke cognitive dysfunction
Donnelly et al. 2020 [15]; Irish Cross-sectional survey;
Investigate the odds of nursing home
residents who had experienced stroke
having cognitive dysfunction compared
to residents without stroke at the time
of admission.
643 residents in 13 randomly selected
nursing homes
Prevalence of cognitive dysfunction and
dementia were significantly higher in
those who had experienced stroke
before admission.
Fitri et al. 2020 [18]; Indonesia Cross-sectional;
Determine the impact of working
memory impairment after stroke on
activities of daily living.
38 patients, 23 (60.5%) males; the main
age was 58.8 ± 10.38 years
Of 38 patients (39.5% women) after
stroke, 17 (44.7%) were
cognitively impaired.
Aam et al. 2020 [19]; Norway Longitudinal; three months and/or18 months after stroke
Investigate the role of the significance of
time and etiologic stroke subtype for the
probability of Post-stroke cognitive
impairment, severity,
and cognitive profile.
617 patients with stroke (mean age
72 ± 12, 42% women)
Executive function and language
improved over the stroke recovery
period; post-stroke cognitive dysfunction
was common for all stroke subtypes at
the two follow-up points. Even a minor
stroke appeared to be a risk factor for
developing cognitive dysfunction.
Morsund et al. 2020 [20]; Norway Longitudinal; followed at 3-month and12-month intervals
Investigate the minor stroke effect on
developing of cognitive and
emotional symptoms
324 patients (120 female) with minor
stroke; the main age was 58.0 ± 10.0 years
The authors observed cognitive
improvement during the follow-up
period, but the prevalence of cognitive
dysfunction remained high (29.5%)
12 months after stroke.
Donnellan and Werring. 2020 [23]. Ireland Systematic review
Identify and quantify studies that
focused on cognitive dysfunction before
and after Intracerebral haemorrhage.
Nineteen studies were included
Prevalence of cognitive dysfunction was
14–88% among 11 studies for
post-intracerebral haemorrhage, which is
typically associated with a higher
prevalence of dementia than
ischaemic stroke.
Post-stroke sarcopenia or cachexia
Scherbakov et al. 2019 [26]; Germany
Longitudinal study; assessed at the acute
phase (4 ± 2 days) and at 12-month
follow-up.
Investigated changes of body
composition and body weight after
ischemic stroke and their association
with functional outcomes.
67 consecutive patients (42% women,
mean age 69 years, mean body mass
index 27.0 kg/m2) with acute ischemic
stroke and mild to moderate
neurological deficit.
One in five patients with ischemic stroke
developed cachexia within 12 months of
stroke. Cachexia was associated with the
lowest functional and physical capacity.
Ryan et al. 2017 [29];
United States of America (USA) Case-control
Determine the prevalence of sarcopenia
in post-stroke survivors using
multiple methods.
190 participants (61% men; aged 40 to
84 years) with mild to moderately
disabled >6 months after onset of stroke.
Reported sarcopenia prevalence
of 14–18%.
Su et al.2020 [30]; Japan Systematic review and meta-analysis Search the prevalence of sarcopenia instroke survivors.
This review included seven studies,
six from Asian countries and one
in the USA.
The pooled prevalence estimate of
post-stroke sarcopenia was 42% (95% CI:
33–52%, I2 = 91%) in patients with stroke.
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Table 1. Cont.
Author, Year; Country/Region Study Type/Follow-Up Period Aim Participant Characteristics Results (Key Findings)
Post-stroke sarcopenia or cachexia
Ohyama et al. 2020 [31]; Japan Cross-sectional
Examined the association between lean
mass and clinical outcomes of acute
ischemic stroke (severe neurological
impairment and functional status
on admission).
164 geriatric patients with acute ischemic
stroke (108 males).
Of 164 Japanese patients (34% women),
101 (62%) were identified as having lean
mass deficits; this study found that lean
mass deficits were not only associated
with worse status of conditions
(i.e., severe neurological impairment and
functional status) at admission but with
poor functional outcomes and longer
duration of hospital stay.
Nagano et al. 2020 [32]; Japan Retrospective cohort study
Investigate the relationship between
changes in skeletal muscle mass and
functional outcomes in patients with
sarcopenia after stroke.
272 patients (mean age 79 years,
70 females; 44% with sarcopenia)
recruited from hospitals.
Preserving muscle mass is associated
with better functional recovery in
post-stroke patients with sarcopenia.
Matsushita et al. 2020 [34]; Japan Cross-sectional
Examined the relationship between
sarcopenia and ability to perform daily
living activities in post-stroke patients
after rehabilitation intervention.
267 participants (56% men),
129 with sarcopenia.
Sarcopenia independently predicts the
inability to engage in daily living
activities after rehabilitation for men;
a potential sex interaction in this
relationship means further investigation
is needed.
Matsushita et al. 2020 [38]; Japan Cross-sectional
Revealed that sarcopenic obesity was
independently associated with lower
ability to perform activities of daily
living in post stroke-patients undergoing
a convalescent rehabilitation program.
Of 376 patients (mean age 78 years),
17% were obese, 32% had sarcopenia and
28% had sarcopenic obesity.
Sarcopenia obesity was independently
associated with lower activities of daily
living capability; however, obesity or
sarcopenia alone were not.
Pre-stroke sarcopenia or cachexia
Minn and Suk 2017 [62]; Japan Cross-sectional Investigate whether increasing musclemass can prevent stroke.
722 participants (age range 50–75 years)
without stroke and dementia.
Increased lean mass may protect against
brain structure changes and against
ischemic stroke, particularly in men.
Nozoe et al. 2019; Japan [63] Cross-sectional Investigated the association betweensarcopenia and the severity of stroke.
In 183 patients (44% women, aged ≥ 65 years;
15% with pre-stroke sarcopenia).
Pre-stroke sarcopenia was a predictor of
severe stroke before and after adjusting
for confounders.
Nozoe et al. 2019 [64]; Japan Prospective cohort study
Investigated the association between
pre-stroke sarcopenia and functional
outcomes after stroke at three months in
patients with acute stroke.
This study involved 152 patients
(47% women, 18 with pre-stroke
sarcopenia) with a mean age of 76 years.
Patients with pre-stroke sarcopenia were
seven times more likely to develop poor
health outcomes at the
assessment endpoint.
Jang et al. 2020 [65]; South Korean Retrospective cohort study
Examined the association between
existing sarcopenia (assessed within two
weeks of hospitalisation) at onset of
stroke and functional recovery six
months after stroke.
This study included 194 hemiplegic
post-stroke patients.
The results revealed that patients with
pre-existing sarcopenia were almost
three times more likely to have poor
clinic health outcomes at six months.
Additionally, they reported a sex-specific
difference, in that women were more
than twice as likely to develop poor
outcomes as men.
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9.2. Common Techniques for Assessing Sarcopenia in Population-Based Studies
Lean mass can be obtained from whole-body scans using DXA, a rapid, accurate,
and non-invasive method for measuring body composition including bone, fat, and lean
tissue. Lean tissue assessed by this technology comprises non-fat and non-bone tissue and
correlates well with skeletal muscle mass quantified by magnetic resonance imaging [67].
Muscle mass and density can be measured by pQCT at the tibial shaft and proximal
forearm sites. In the GOS [10], standard transverse scans were performed at 4% and
66% of the radial and tibial length. Radial and tibial data were obtained and analysed
separately. Density thresholds were used to distinguish bones, muscle, and fat tissue
(fat: <15 mg/mm3; muscle: 15–180 mg/mm3; bone: >180 mg/mm3) [68].
Magnetic resonance imaging (MRI) has the best image resolution and a high level of
accuracy and is central to much research in brain-imaging studies. While MRI does not use
X-rays or other ionising radiation, it is expensive and not widely available [69].
A more direct measure of muscle mass uses bioelectric impedance analysis (BIA)
to determine total body water, lean mass, and body fat. BIA detects impedance to the
flow of a small current (approximately 1–10 µA), usually measured between the wrist and
opposite ankle via two or four electrodes that make contact with the skin. While BIA is an
inexpensive tool that is portable and rapid, it has limited accuracy [69–71]
Handgrip strength (kg) can be measured using hand-held dynamometry [72]. The test-
ing procedure should be explained and demonstrated to each participant before mea-
surement. With the participant seated in a comfortable position and the arm holding the
dynamometer flexed at the elbow to 90 degrees, the participant is asked to squeeze the
device as hard as possible for several seconds and the peak reading is recorded.
Leg muscle strength can be assessed using a break test technique to measure peak
eccentric muscle strength in the legs using a hand-held dynamometer that is a reliable
method for assessing lower-limb muscle strength in adults, and the population-based
normative data for Caucasians are available to clinically identify people who are at low
levels of leg muscle strength [73].
Usual gait speed (shoes on) is typically determined by measuring how many seconds
the participant takes to walk a distance of four metres and is recorded as the walking speed
(m/s) [9].
Another test of physical performance is “the timed-up-and-go (TUG) test”, where the
time taken to stand up from a chair and walk to a marked line (usually over a distance of
3 m) then return and sit down again is recorded. This test involves both walking speed
and balance [74].
The short physical performance battery (SPPB) is a validated tool that evaluates
lower extremity physical performance using three tests: standing balance, walking speed,
and chair stand tests [75]. The score ranges from 0 to 12 (worst to best performance) by
combining the three times for the subtests [75].
9.3. Functional Near-Infrared Spectroscopy
Functional Near-Infrared Spectroscopy (fNIRS) is a neuroimaging technique that is
non-invasive, cost-effective, safe, rapid to set up, portable, and non-motion-sensitive [76].
Due to these advantages, fNIRS has been widely used in studies of particular clinical
populations, such as Alzheimer’s disease, depression, and other chronic neurological dis-
orders [77]. fNIRS maps neuronal activity by applying near-infrared spectrum light that
can travel through tissue. It is sensitive to brain neurovascular changes during neuroac-
tivity, as the secondary measurement for neuro-connectivity localisation changes through
detecting subtle brain blood flow changes (not measuring neuronal activities directly) [78].
To be more specific, near-infrared light is absorbed by oxygenated haemoglobin and
deoxygenated haemoglobin in the cortex. An increase in oxygenated haemoglobin is
considered an indicator of neuronal activity, and a canonical hemodynamic response in-
volves an increase in oxygenated haemoglobin accompanied by a decrease in deoxygenated
haemoglobin [78].
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Butler et al. noted that fNIRS has been used widely to investigate brain activities in
response to transcranial magnetic stimulation in patients with stroke, and recommended
using fNIRS for speech and language studies in stroke [79]. Another literature review
examined how fNIRS may be applied to the study of gait disorders in stroke and discussed
its application for assessing rehabilitation programs [80]. Most studies in this field are
case-control studies in clinical populations with a low statistical power; no longitudinal
observational studies have addressed risk factors for stroke in the context of concurrent
post-stroke sarcopenia and cognitive impairment.
10. Conclusions
The literature to date contains little evidence about the links between post-stroke
sarcopenia and cognitive function. Post-stroke sarcopenia and cognitive dysfunction
may be comorbid and associated as they often occur simultaneously and share some
similar underlying mechanisms. A future direction for stroke rehabilitation research
might be to involve testing combinations of interventions for cognitive function and
physical performance.
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